BioSpace News Archive

Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced it will present at the H.C. Wainwright 22 nd Annual Global Investment Conference on Tuesday, September 15 at 3 p.m. ET. Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder will present virtually to provide an update on the development of Ocugen’s breakthrough

CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), one of the largest integrative healthcare systems in the United States, is pleased to announce that it intends to complete a non-brokered private placement of up to 20,000,000 units (" Unit ") of the Company at a price of $0.15 per Unit for aggregate gross proceeds of up to CAD $3,000,000 (the “ Offering ”). Each Unit will consist of one common share (" Common Share ") in the capital of

Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that company management will participate in fireside chats at two investor conferences in September: Baird 2020 Global Healthcare Conference Date: Thursday, September 10 Time: 9:40 a

Cue Biopharma, Inc. announced it will present at the Baird Global Healthcare Conference on Wednesday, September 9, 2020, the Morgan Stanley Global Healthcare Conference on Thursday, September 17, 2020 and the Oppenheimer & Co. Fall Healthcare Life Sciences and MedTech Summit on Wednesday, September 23, 2020.

Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that management will participate in Citi’s 15 th Annual Virtual BioPharma Conference, September 9-10, 2020. Bruce Goldsmith, Ph.D., president and chief executive officer, will participate in a panel entitled “Disease Modifying Therapies of Neurodegenerative Diseases”

Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Mark Pruzanski, M.D., President and Chief Executive Officer and Sandip Kapadia, Chief Financial Officer of Intercept, will present at the Wells Fargo 2020 Virtual Healthcare Conference on Wednesday, September 9, 2020 at 12:00 p.m. ET. A l

RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that Brian Wong, M.D., Ph.D., President and CEO, will present a corporate update and company overview at the following conferences: Wells Fargo 2020

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics, is scheduled to present at the Wells Fargo 2020 Virtual Healthcare Conference on Thursday, September 10, 2020, at 11:20 a.m. ET. A live webcast of the event will be available on the “Eve

Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced today that management will participate in the Advanced Therapies Congress & Expo being held virtually September 8-11, 2020. Title: Repair of the microcirculation reverses ischemic tissue damage Presenter: Dougl

TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today that Charles Theuer, M.D., Ph.D., President and CEO, will present a corporate overview at the